Sintalica develops breakthrough treatments for neuroinflammatory diseases
Sintalica is a drug discovery company focused on Psilocybin and tryptamine derivatives for psychedelic-assisted therapies for a variety of targeted health conditions.
We are uniquely specialized in proprietary synthesizing psychedelics, formulating drugs, and developing new treatments.
Our team of experienced professionals stays current about the latest drug developments.
​
​
10+
U.S. FILED PATENTS
IP Portfolio Protecting
Novel Compounds and Formulations.
30+
BILLION COMPOUNDS SCREENED
Leading AI-Enhanced Drug Development
4
FEDERAL RESEARCH GRANTS RECEIVED
Maximizing R&D While Reducing Traditional Costs.
OUR APPROACH TO R&D
SCIENTIFIC TEAM
Our scientific team is led by world-class experts in neurodegenerative diseases, pharmacology and chemistry.
We are specialized in developing novel proprietary psychedelic molecules resulting in more controlled and safer experiences, and no hallucinogenic effects. Our intellectual property is secured.
EXCLUSIVE PARTNERSHIP
Through our exclusive partnership with the University of Messina we discover, synthesize and trial novel psychedelics molecules in one place.
​
We have full expertise in drug and clinical development, regulatory affairs and psychedelic-specific manufacturing.
OUR FOCUS
Scientific studies show that certain psychedelic molecules have powerful anti-inflammatory properties. Our proprietary molecules can help control peripheral and central neuroinflammation without hallucinogenic effects.
BOARD OF DIRECTORS
BRUCE LINTON
Co-Founder & Chairman
FABIAN MONACO
Board Member
JOHN DiGIROLAMO
Board Member